Analytics cookies help us understand what works in the catalog. Accept all, reject non-essential ones, or choose categories below. Privacy policy
P21 (P021) — a CNTF-derived neurotrophic peptide mimetic studied for neurogenesis and BDNF signaling in neurodegeneration models. Lyophilized, HPLC ≥98%. Research use only (RUO).
Size: 10 mg
No published analyses yet.
Titration schedule · reference
The information below is provided from public sources for reference only. It is not advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start | 100–250 mcg/day, subcutaneous | Starting dose |
| Typical regimen | 250–500 mcg/day, 4–6 week course | Increase if needed |
| Upper bound cited in protocols | up to ~1000 mcg/day | Maximum in this schedule |
Share your experience
No reviews yet. Tell others what you think of this product.
P021 (also “P21”) is a synthetic small neurotrophic compound (Ac-DGGL(A)G-NH₂) derived from the biologically active region of ciliary neurotrophic factor (CNTF). It was engineered in academic neuroscience as a compact, metabolically stable, orally active mimetic of CNTF’s neurogenic activity — chemically distinct from the unrelated p21 / CDKN1A cell-cycle protein that shares the shorthand.
In preclinical research (cell cultures and rodent models of Alzheimer’s disease and ageing) P021 has been reported to enhance hippocampal neurogenesis, raise BDNF and reduce abnormal tau hyperphosphorylation. It is a frontier, rarely-stocked research compound rather than a mainstream peptide.
Supplied as a lyophilized powder. See the monograph and handling notes for details and references.
